拨康视云引入基石投资者 助力眼科创新药研发

DoNews
Jun 24, 2025

眼科创新药研发商拨康视云近日宣布,在本次发行中成功引入两名基石投资者,累计认购金额达2280万美元(约1.79亿港元)。其中,知名天使投资人龚虹嘉全资持有的富策控股认购2000万美元,瑞凯集团认购280万美元。拨康视云专注于小分子多激酶抑制剂和抗体-小分子协作偶联技术平台的开发,覆盖眼表、青光眼及眼底疾病领域。此次融资将加速其创新药物的研发进程,为眼科疾病治疗提供更多解决方案。基石投资者的加入,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10